Bronchodilating and density dependence effects of fenoterol, ipratropium bromide and Duovent in reversible chronic obstructive pulmonary disease.
The bronchodilating effect of Duovent (0.2 mg fenoterol +0.8 mg ipratropium bromide) was compared with that of each of its components at the same doses. Twenty patients were included in the trial. Maximum expiratory flow-volume curves with air and helium-oxygen, intrathoracic gas volume and airway conductance were used for assessing the bronchomotor tone before and 15, 30, 60, 240 and 360 min after drug administration. All the drugs showed a significant bronchodilating effect. No differences between Duovent and fenoterol or ipratropium bromide were observed except a slight but statistically significant greater decrease of ITGV with Duovent. When expressing the data as percentage variation of the initial values, Duovent induced a better effect than the other drugs. The evaluation of density dependence was highly disappointing, and no conclusion can be drawn.
D000403:Airway Resistance; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D005740:Gases; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D013909:Thorax / Q000503:physiopathology; D014797:Vital Capacity
D001286:Atropine Derivatives; D001993:Bronchodilator Agents; D004338:Drug Combinations; D005740:Gases; C030809:fenoterol, ipratropium drug combination; D005280:Fenoterol; D009241:Ipratropium